Valley National Advisers’s Cardiol Therapeutics CRDL Stock Holding History

Valley National Advisers’s Portfolio CRDL Stock Details CRDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.3K	Hold	5,000	–	–	﹤0.01%	709
2026 Q1	$6K	Hold	5,000	–	–	﹤0.01%	663
2025 Q4	$4K	Hold	5,000	–	–	﹤0.01%	700
2025 Q3	$5K	Hold	5,000	–	–	﹤0.01%	650
2025 Q2	$6K	Hold	5,000	–	–	﹤0.01%	630
2025 Q1	$4K	Hold	5,000	–	–	﹤0.01%	656
2024 Q4	$6K	Hold	5,000	–	–	﹤0.01%	605
2024 Q3	$9K	Hold	5,000	–	–	﹤0.01%	531
2024 Q2	$10K	Hold	5,000	–	–	﹤0.01%	611
2024 Q1	$9K	Hold	5,000	–	–	﹤0.01%	657
2023 Q4	$4K	Hold	5,000	–	–	﹤0.01%	816
2023 Q3	$4K	Hold	5,000	–	–	﹤0.01%	724
2023 Q2	$5K	Hold	5,000	–	–	﹤0.01%	678
2023 Q1	$4K	Hold	5,000	–	–	﹤0.01%	692
2022 Q4	$3K	Hold	5,000	–	–	﹤0.01%	702
2022 Q3	$3K	Hold	5,000	–	–	﹤0.01%	733
2022 Q2	$6K	Hold	5,000	–	–	﹤0.01%	640
2022 Q1	$8K	Hold	5,000	–	–	﹤0.01%	627
2021 Q4	$9K	Buy	+5,000	New	+$13.8K	﹤0.01%	618

Other funds holding CRDL

MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Integrity Alliance Urbandale, Iowa $3.2B AUM 23.28% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Valley National Advisers's CRDL Position: Q2 2026 in Review

Valley National Advisers held its Cardiol Therapeutics (CRDL) position steady in Q2 2026 at 5,000 shares worth $5.3K. The position accounts for ﹤0.01% of the portfolio, ranked #709.

Valley National Advisers first reported a position in CRDL in Q4 2021 and has held it in 19 quarters since. The position peaked at $10K in Q2 2024. 51 funds tracked by Wall St. Rank hold CRDL as of Q2 2026.

Valley National Advisers held 5,000 shares of Cardiol Therapeutics worth $5.3K as of Q2 2026.
Valley National Advisers left its Cardiol Therapeutics share count unchanged in Q2 2026.
Cardiol Therapeutics made up ﹤0.01% of Valley National Advisers's portfolio in Q2 2026, its #709 holding.
Valley National Advisers first reported a position in Cardiol Therapeutics in Q4 2021 and has held it in 19 quarters since.
Valley National Advisers's Cardiol Therapeutics position peaked at $10K in Q2 2024.
51 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2026.

Based on Valley National Advisers's 13F filing for Q2 2026, filed 29 Jul 2026.